Screening to find cancer early, when it’s most treatable

TESTS FOR CANCER SCREENING
For asymptomatic adults at average risk of cancer, our blood test aims to ensure that all individuals eligible for cancer screening are screened. We believe that by offering an accurate, simple blood test, we can transform cancer screening and help increase compliance rates. We are starting with colorectal cancer, where screening rates can be improved, and will continue to expand to other cancer types.

Guardant Shield: A blood test to screen for early signs of cancer

Today, 1 in 3 adults are not completing the recommended colorectal cancer screening.21 A blood test can improve these rates by overcoming barriers associated with available methods, including colonoscopy and stool-based testing, which while effective, can be unpleasant, time-consuming and difficult to complete.

Guardant Reveal: Improving the management of early-stage cancer

TESTS FOR PATIENTS WITH EARLY-STAGE CANCER
For doctors treating patients of early-stage cancer, two fundamental questions remain after surgery: Does any cancer remain? What is the risk of the cancer returning? Our test helps answer these questions by quickly and conveniently detecting minimal residual disease (MRD) from a simple blood draw.  

Residual disease detection and recurrence monitoring

Guardant Reveal™ is a revolutionary blood-only liquid biopsy test that detects circulating tumor DNA (ctDNA) for minimal residual disease (MRD) assessment in early-stage colorectal, breast, and lung cancers. In addition to detection of MRD, Guardant Reveal is also available to monitor recurrence in previously diagnosed patients. Guardant Reveal is covered for fee-for-service Medicare patients with Stage II or III CRC whose testing is initiated within three months following curative intent therapy.